Published in final edited form as:

Am J Reprod Immunol. 2015 March ; 73(3): 199–213. doi:10.1111/aji.12355.

VIRAL INFECTIONS DURING PREGNANCY

Michelle Silasi, Ingrid Cardenas, Karen Racicot, Ja-Young Kwon, Paula Aldo, and Gil Mor

Department of Obstetrics Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA

Abstract

Viral infections during pregnancy have long been considered benign conditions with a few notable exceptions, such as herpes virus. The recent Ebola outbreak and other viral epidemics and pandemics show how pregnant women suffer worse outcomes (such as preterm labor and adverse fetal outcomes) than the general population and non-pregnant women. New knowledge about the ways the maternal-fetal interface and placenta interact with the maternal immune system may explain these findings. Once thought to be “immunosuppressed”, the pregnant woman actually undergoes an immunological transformation, where the immune system is necessary to promote and support the pregnancy and growing fetus. When this protection is breached, as in a viral infection, this security is weakened and infection with other microorganisms can then propagate and lead to outcomes, such as preterm labor. In this manuscript, we review the major viral infections relevant to pregnancy, and offer potential mechanisms for the associated adverse pregnancy outcomes.

Perinatal outcomes from viral infections during pregnancy can range from no effect to pregnancy loss by spontaneous abortion to fetal infection with resulting congenital viral syndromes. Prenatal care currently holds no true standard for antenatal management of viral infections during pregnancy, aside from those known as TORCH infections (toxoplasmosis, “other”, rubella, CMV, and HSV). And while these guidelines allow for a diagnosis of infection, no treatment or preventative strategy is available to prevent adverse pregnancy outcomes.

The importance of understanding the role of viral infection during pregnancy is becoming more relevant as we confront growing risks of pandemics, which may significantly affect the pregnant mother and the fetus¹. There is strong epidemiologic evidence that pregnant women are at higher risk of severe illness and mortality from viral infections^{2, 3}, noticeably during pandemics such as influenza, EBOLA and Lassa fever^{4, 5}. Furthermore, viral infection may predispose the pregnancy to preterm labor and preterm delivery by infection with other superimposed microorganisms^{6–8}. Consequently, understanding why pregnant women are at higher risk is vital in order to design the appropriate approaches for treatment as well as for prevention.

In this manuscript we review the main viral infections reported associated with pregnancy and discuss potential mechanisms that explain why pregnant women are a high- risk population.

HERPES SIMPLEX VIRUS

Genital herpes simplex virus (HSV-2) is the most common sexually transmitted infection among the adult female population of the United States. The Centers for Disease Control and Prevention (CDC) estimates that about 1 out of 6 people overall (1 out of 5 women aged 14–49 and 1 out of 9 men aged 14–49) in the United States has genital HSV, with almost 800,000 new cases identified each year⁹.

HSV-1 (HSV-1) and 2 (HSV-2) are part of a large family of DNA viruses of which eight are known to be infectious in humans. HSV-1 and 2 are transmitted across epithelial mucosal cells as well as through skin interruptions and migrate to nerve tissues where they persist latent. HSV-1 predominates in orofacial lesions and typically is found in the trigeminal ganglia, while HSV-2 is most commonly found in the lumbosacral ganglia. Both HSV-1 and HSV-2 can cause genital lesions and shedding.

According to The National Health and Nutrition Examination Surveys (NHANES), there is an overall decrease in the seroprevalence of HSV-1 by 7% and of HSV-2 by 19% [2]. NHANES indicates that the rates of HSV-2 are higher among women (23.1%) than men (11.2%) in the general population. Factors that affect a woman's risk of infection before pregnancy include ethnicity, poverty, cocaine abuse, earlier onset of sexual activity, number of lifetime sexual partners, sexual behavior, and the presence of bacterial vaginosis¹⁰.

The overall seroprevalence of HSV among pregnant women is 72%¹¹. This represents any exposure to either HSV-1 or HSV-2 that resulted in infection and antibody formation. During pregnancy, HSV infection has been associated with spontaneous abortion, intrauterine growth restriction, preterm labor, and congenital and neonatal herpes infections¹². However, the clinical management revolves around decreasing vertical transmission to the fetus, thereby decreasing the risk of neonatal herpes infection.

The presence of antibodies to both HSV-1 and HSV-2 at the onset of pregnancy (prior seroconversion) has the least risk of perinatal transmission. In contrast, primary or first genital HSV infection late in pregnancy carries a 30% to 50% risk of neonatal infection, while early pregnancy infection carries a risk of less than 1%^{9, 13}. If primary HSV infection occurs during late pregnancy antibodies are not developed in time to suppress viral replication and shedding before labor. Transplacental or ascending transmembrane transmission of HSV from mother to fetus during pregnancy is uncommon; 80–90% of perinatal transmission occurs during labor and delivery¹⁴. However, neonatal infection with HSV can also occur in the setting of recurrent herpes. Symptom recurrence producing viral shedding at the onset of labor is associated with up to a 3% risk of neonatal herpes; both young age and recent infection are associated with increased viral shedding^{15, 16}. Interestingly, asymptomatic viral shedding in recurrent disease at term has not been associated with neonatal disease¹⁴.

Neonatal herpes infection is classified into three categories: localized skin, eye, and mouth (SEM); central nervous system (CNS) with or without SEM; and disseminated disease (which carries a mortality rate in excess of 80%, if untreated.)^{14, 15, 17, 18}. Infected newborns can exhibit significant neurologic deficits, blindness, seizures, and learning disabilities.

Suppressive antiviral therapy during the last month of pregnancy reduces the likelihood of asymptomatic viral shedding, clinical HSV recurrence, and caesarean delivery for recurrent lesions^{19–22}. When lesions or prodromal symptoms are present at the onset of labor, caesarean section is recommended to minimize the risk of viral exposure to the infant, even if suppressive therapy has been used²³.

Among women with asymptomatic HSV in labor, invasive procedures such as amniotomy, the use of fetal scalp electrodes²⁴ and operative vaginal delivery²⁵, should be avoided. This decreases fetal exposure to vaginal secretions potentially containing the virus. Active management should be considered in these women when membranes rupture before the onset of labor.

When there is preterm premature rupture of the membranes (PPROM), the risks of prematurity must be weighed against the risks of HSV transmission. Each case will be dependent on the gestational age and clinical picture. There is no consensus on the best timing of delivery for women with PPRM and a history of HSV.

VARICELLA ZOSTER VIRUS

Varicella, also known as chickenpox, is the acute primary disease of varicella zoster virus. It is a common, highly contagious, self-limiting disease seen mainly during childhood. It is transmitted by respiratory droplets or close contact and causes a widespread maculopapular to vesicular rash that starts on the face and trunk and then moves to the extremities. The virus incubates for 15 days and is communicable 2 days before the onset of the rash until all the lesions have crusted or disappear²⁶. After an initial episode with varicella zoster leading to chickenpox the virus may persist latent in the dorsal root ganglia for years. Reactivation results in herpes zoster, which is more common in adults.

The incidence of varicella in pregnancy is 0.7/1000. Because varicella is mainly a disease of childhood in the United States, most women are immune before they become pregnant²⁷. However, primary varicella infection during pregnancy is associated with significant maternal and fetal morbidity and mortality. While the childhood illness is self-limiting and mild, if varicella pneumonia develops during pregnancy, it can run a more fulminant course. Approximately 10–20% of pregnant women who are infected with varicella will develop pneumonia, which carries a mortality rate of up to 40%⁹.

Fetal morbidity and mortality is related to the development of congenital varicella syndrome. This syndrome is characterized by limb hypoplasia, microcephaly, hydrocephaly, cataracts, intrauterine growth restriction, and mental retardation²⁸. The risk of congenital varicella syndrome ranges from 0.4–2% with maternal varicella infection during the first 20 weeks of gestation^{29–31}²⁸. Development of this syndrome is thought to be a result of

reactivation of the varicella virus in utero, as opposed to primary infection of the fetus^{30, 32, 33}.

Herpes zoster in pregnancy is much less common than varicella, occurring in 1/10,000 pregnancies, or 0.1%²⁶. The risk of the congenital varicella syndrome is negligible, because antibodies in the maternal blood prevent the virus from crossing the placenta and infecting the fetus. In 1994, Enders and colleagues showed no clinical evidence of infection in infants born to 366 women with herpes zoster in pregnancy²⁹.

Neonatal infection may occur in 10% to 20% of neonates whose mothers became acutely infected from 5 days before delivery to 2 days after the delivery. It results from hematogenous dissemination of the virus across the placenta in the absence of maternal antibodies. Infants become symptomatic 5–10 days postpartum. The clinical picture may vary from skin lesions to systemic illness, which has a mortality rate of about 30%^{33–37}.

Treatment for the pregnant woman primarily targets decreasing maternal morbidity, as no treatment regimen has shown a decrease in the incidence of vertical transmission.

CYTOMEGALOVIRUS

Cytomegalovirus (CMV) is a ubiquitous virus with variable clinical manifestations. Seroprevalence increases with age, and differs based on geographic area and socioeconomic status. CMV infects 60% of women of childbearing age in developed countries and 90% in developing countries³⁸. The resulting seropositivity (maternal antibody status to CMV) is the most important factor in combatting congenital CMV infection. The remaining 40% of women in developed countries (such as the United States) are susceptible to infection; and if this infection occurs during pregnancy, it can have detrimental effects on the pregnancy.

Person-to-person transmission occurs by contact with infected nasopharyngeal secretions, urine, saliva, semen, cervical and vaginal secretions, breast milk, tissue, or blood. Primary maternal infection occurs in 1% to 4% of susceptible women and reactivation may occur in approximately 10% of seropositive women. Maternal infection with CMV during the antepartum period goes undetected the majority of the time, but can manifest as a mild febrile illness with nonspecific symptoms such as fatigue, myalgias, rhinitis, pharyngitis, and headache. Furthermore, pregnancy does not appear to affect the clinical severity of the infection.

Vertical transmission (from the mother to the fetus or newborn) occurs most commonly after maternal primary infection, usually by the following mechanisms: transplacental after the virus infects the placenta, intrapartum via ingestion or aspiration of cervicovaginal secretions during delivery, postpartum via breastfeeding, and ascending from the maternal genital tract antepartum (rare).

In terms of fetal effects of maternal infection, CMV is the most common congenital viral infection, with a birth prevalence of about 0.5% (range 0.2–2.5%)^{39, 40}. CMV primarily affects the ventricle, the organ of Corti and the neurons of the eighth cranial nerve, which explains why it is the leading cause of congenital hearing loss. Furthermore, human neuronal

cells are able to be infected in-vitro with CMV, which may explain the central nervous system effects during fetal development⁴¹.

The rate of fetal transmission appears to increase with advancing gestation. A review that pooled data from nine studies of maternal-fetal CMV transmission reported first, second, and third trimester transmission rates of 36.5, 40.1, and 65 percent, respectively^{42, 43}. However, while the rate of transmission correlates with advancing gestation, the severity of the disease is inversely related to gestational age.

Most newborns of women with primary CMV infection and almost all newborns of women with non-primary infection in pregnancy are initially asymptomatic. Ten to 15 percent of these initially asymptomatic newborns develop neurodevelopmental damage within the first three years of life^{44, 45}. Approximately 5 to 20 percent of newborns of mothers with primary CMV infection will have symptoms at birth. The mortality rate of these newborns is about 5 percent. Five to 15 percent of the asymptomatic newborns will develop sequelae later in life⁴⁶⁻⁴⁸.

Prenatal diagnosis of fetal CMV is based on amniocentesis performed 6 weeks after the presumed time of infection and after 21 weeks of gestation. While sonographic findings often imply a poor prognosis, their absence does not guarantee a normal outcome. The value of quantitative determination of CMV DNA in the amniotic fluid and the effectiveness of prenatal therapy has not been proven⁴¹. Given this fact and the ubiquitous nature of the virus, universal screening for pregnant women is currently not recommended.

RUBELLA

The name rubella is derived from Latin, meaning “little red” because it was initially thought to be a variant of measles or scarlet fever. However, in the mid 1800s a German physician distinguished rubella as a distinct clinical entity, hence it being commonly known as German measles. The rubella virus, an enveloped RNA virus, is classified as a togavirus. It is transmitted through respiratory droplets and is primarily a mild disease in children. In adults, rubella is a self-limited disease characterized by rash. The rash characteristically begins on the face and spreads to the trunk and extremities. The incubation period is 12 to 23 days. The infectious period is from 7 days before to 7 days after rash onset⁴⁹.

Importantly, rubella can be asymptomatic in 25% to 50% of the cases. When maternal infection occurs in the first trimester, fetal infection rates are up to 50%, dropping to <1% after 12 weeks. (Peripartum maternal infection does not seem to increase the risk of CRS.) Diagnosis of primary maternal infection should be made by serologic tests. Diagnosis of fetal infection includes detection of fetal serum IgM (but not until after 22–24 weeks of gestation) or viral culture of the amniotic fluid.

Pregnancy outcomes as a result of maternal rubella infection include spontaneous abortion, fetal infection, stillbirths or fetal growth restriction and the congenital rubella syndrome (CRS). The CRS, represents the neonatal manifestations of antenatal infection with the rubella virus. The risk of CRS varies according to the gestational age at which maternal infection occurs⁵⁰. Therefore, counseling regarding the fetal risk and management must be

individualized. Two proposed mechanisms for rubella cytopathology includes virus-induced inhibition of cell division⁵¹ and direct cytopathic effects⁵⁰.

Fortunately, however, since the development of the rubella vaccine in the 1960s, along with the implementation of universal screening and vaccination pre-pregnancy and postpartum for childbearing women, the incidence of congenital rubella infection has decreased substantially in the United States [40]. Even so, not all pregnant women are immune to rubella. Certain populations are not immunized because they are missed, refuse immunization, or come from countries where rubella vaccination is not part of the routine immunization program^{9, 52}.

HIV

According to the Centers for Disease Control and Prevention (CDC), about 50,000 people get infected with HIV each year in the United States. In 2010, of the 1.1 million people in the United States living with HIV, 47,500 people had new HIV infections and 1 in 4 people were women⁵². About 80% of new cases in women in the United States are contracted through heterosexual intercourse, 20% by contaminated needles, and the remaining cases through blood transfusions (no longer occurring as transmission factor due to universal screening of blood products for HIV) and maternal-child transmission. In the United States, African American and Hispanic women represent 25% of the female population but 82% of the total number of women with AIDS. Furthermore, black women alone account for 80% of newly diagnosed HIV/AIDS cases²⁸.

Eventually, most people infected with HIV develop AIDS and die from opportunistic disease or malignancy. Without treatment, 90% of people with HIV progress to AIDS after 10–15 years. Treatment with antiretroviral medication prolongs life expectancy even after progression to AIDS such that the average survival with antiretroviral treatment exceeds 15 years^{53, 54}.

The most common clinical manifestations of the acute retroviral syndrome include fever, lymphadenopathy, sore throat, rash, myalgia/arthritis, and headache. Diagnosis is made with HIV immunoassay (ELISA or western blot) and HIV viral RNA detection. If left untreated levels of CD4 T cells decline and opportunistic infections lead to death. However, as described above, with antiretroviral treatment, life expectancy has increased significantly.

The reduction in mother-to-child transmission of human immunodeficiency virus (HIV) is regarded as one of the most effective public health initiatives in the United States. While pregnancy does not affect disease course, HIV infection in pregnancy includes a risk of vertical transmission. The exact mechanism of mother-to-child transmission of HIV remains unknown at this time. This transmission may occur during intrauterine life, delivery, or breastfeeding. The greatest risk of transmission is attributed to advanced maternal disease, likely due to a high maternal HIV viral load. With no treatment, the risk of vertical transmission is as high as 25%, but with the implementation of universal antenatal HIV testing, counseling, maternal antiretroviral medication and neonatal post-exposure prophylaxis for newborns of women with HIV, delivery by caesarean section prior to onset

of labor, and discouraging breastfeeding, the mother-to-infant transmission has decreased to less than 1% in the United States⁵².

The hormonal status, the regulation of the mucosal environment in the female reproductive tract and the morphological changes in the female reproductive tract associated with pregnancy play a critical role in the susceptibility to HIV. This is an area that we have only begun to understand and involves multiple complex biological and clinical factors that need to be carefully evaluated⁵⁵. Several reviews on the subject have been recently published where these aspects are further elaborated^{56–59}.

HEPATITIS

Acute viral hepatitis is the most common cause of jaundice in pregnancy. The course of most viral infections is not affected by pregnancy.

Hepatitis A

Hepatitis A virus (HAV) infection is the second most common form of viral hepatitis in the United States. It is an RNA virus that is transmitted by the fecal oral route^{60–62}. Infections occur early in life in areas where sanitation is poor and living conditions are crowded⁶³. The incidence of acute HAV infection in pregnancy is approximately 1:1000 women. Vertical transmission of HAV during the pregnancy or puerperium is rare^{64–68}. Pregnancy should not impact a physician's management of HAV infection or vice-versa.

Hepatitis B

Hepatitis B virus (HBV) is the most common form of chronic hepatitis around the world. Chronic carriers can continue to transmit the disease for many years before becoming symptomatic⁶⁹. Infection occurs very often in early childhood when it is asymptomatic and then leads to the chronic carrier state. Chronic HBV infection leads to increased risk for chronic hepatic insufficiency, cirrhosis and hepatocellular carcinoma.

In the United States, the incidence of HBV infection has declined from 8.5 cases to 1.5 cases per 100,000 from 1990–2007. Approximately 0.5% of the US population is HbsAg positive, and 5% is anti-HBc positive⁷⁰.

The age group most likely to be affected worldwide is the newborn population, particularly in areas with high prevalence of disease and lack of diagnosis of infected women whose infants are at risk of becoming chronic carriers. In the other hand, the primary causes of transmission in the young adult population where perinatal screening and adequate newborn prophylaxis exist are the exposure to contaminated blood products, body fluids, or sexual contact.

Acute HBV infection during pregnancy usually is mild and not associated with teratogenicity or mortality. Treatment is mainly supportive, with monitoring of liver biochemical tests and prothrombin time. Unless the patient has acute liver failure or protracted severe hepatitis, antiviral therapy is usually unnecessary. Chronic HBV infection is generally well-tolerated in women who do not have advanced liver disease. But, because

these patients occasionally will develop a hepatitis flare, liver biochemical tests should be monitored every trimester and postpartum.

A high maternal viral load appears to be the most important risk factor for perinatal transmission. Transplacental transmission and transmission due to obstetrical procedures are less frequent causes, while breastfeeding does not appear to pose a substantial risk. Delivery decisions should be made in the context of the usual obstetric indications.

Management options are available to decrease the risk of perinatal transmission. Universal screening of all pregnant women allows for identification of Hepatitis B surface antigen positive women. Women found to be positive should also be screened for HIV and other forms of hepatitis such as hepatitis A and hepatitis C. Monitoring of liver biochemical tests and viral load help guide management and extent of disease. All infants of mothers with HBV should receive passive-active immunization with hepatitis B IgG and the hepatitis B vaccine within 12 hours of delivery.

Hepatitis C

The hepatitis C virus (HCV) is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma around the world⁷¹. HCV infection has a slow onset with symptoms in about 25% of patients [59]. Approximately 40% of patients infected with HCV recover completely and the rest become chronic carriers. Twenty percent of the carriers develop cirrhosis and of those, up to 20% develop liver cancer⁷⁰.

HCV-related end stage liver disease is the most common chronic blood borne infection and the leading reason for liver transplantation in the United States. New HCV infections have decreased by more than 80% since 1990⁷². There are an estimated 4 million cases of chronic liver disease and 2.7–3.4 million cases of HCV infection^{73, 74}. There are 25,000–38,000 new cases of HCV diagnosed every year with a prevalence of 1.6%^{73, 75}. Of the newly diagnosed cases, only 6,300 (17%) are symptomatic⁷⁶.

Acute HCV infection leads to symptomatic hepatitis in fewer than 20% of patients; 15% of acute liver disease in the United States is due to HCV⁷⁷. The peak age of incidence of acute HCV is between 20–39 years⁷⁸. In the pregnant population, the prevalence of HCV is estimated to be less than 1–5% with the highest prevalence in the African American population (6.1%) and the lowest in the Latin population (2.8%)^{79, 80}. Approximately 75% of asymptomatic patients are chronically infected. They are a source of transmission to others and are at risk for chronic liver disease or other HCV-related chronic diseases.

Approximately 60% of all new infections occur via intravenous (IV) drug use⁸⁰, 10–20% by sexual transmission⁸¹, less than 6% by blood transfusion, and the remainder includes occupational and unknown exposures⁸². Only 25% of pregnant women report receiving blood products or IV drug use when HCV infection is diagnosed⁸³. Concurrent alcoholism, IV drug use (38%), and coexisting HIV infection (33%) are important associated risk factors^{82, 84}. The decline observed in the incidence and prevalence of HCV is attributed to needle exchange programs among intravenous drug users and improved blood donor

screening. This has led to a relative increase in the importance of accidental needle sticks, and sexual and perinatal transmission in the incidence of HCV infections.⁷¹

The World Health Organization (WHO) estimates that about 3% of the world's population has been infected with HCV and that there are more than 170 million chronic carriers who are at risk of developing liver cirrhosis and/or liver cancer⁸⁵. The highest prevalence is in Egypt (18–22%) and the lowest in Sweden (0.003%)^{71, 85}. As many as 2–4 million persons may be chronically infected in the United States, 5–10 million in Europe, and about 12 million in India. Of these, about 25% are symptomatic, but 60–80% may progress to chronic liver disease, and 20% of these develop cirrhosis⁸⁵.

Women chronically infected with hepatitis C may have uneventful pregnancies; though vertical transmission is the greatest concern. In the United States and other industrialized nations, because of vaccination programs against hepatitis B, hepatitis C virus (HCV) has become the primary cause of chronic viral hepatitis in children, with vertical transmission becoming the leading source of infection^{86–88}. The mechanism underlying vertical transmission is poorly understood. Overall the transmission rate appears to be less than 2 percent, when adjusted for certain clinical variables. For example, HIV co-infection results in a 19 percent transmission rate^{89, 90}. During pregnancy, pregnant women should be seen regularly by a gastroenterologist to monitor liver biochemical tests and viral load. During labor, prolonged rupture of membranes should be avoided, as well as invasive obstetric procedures⁹¹. Caesarean delivery should be reserved for the usual obstetrical indications. Breastfeeding is not contraindicated.

Hepatitis E

Hepatitis E is caused by the hepatitis E virus (HEV). Although initially thought to be hepatitis A, most waterborne epidemics of hepatitis in developing countries are known to be due to hepatitis E. It is rare and sporadic in industrialized countries⁹². It is usually passed by fecal–oral transmission through a contaminated water supply⁹³. The infection is typically mild and self-limited without chronicity or clinical sequelae.

During pregnancy, the risk of fulminant disease and maternal mortality occurs in 20% of patients when disease presents during the third trimester. Premature deliveries with high infant mortality of up to 33% are also observed⁹⁴. Although the mechanism underlying the increased mortality is unknown, the reported complications include gestational hypertension, preeclampsia, proteinuria, edema, and kidney disease. One possible mechanism of disease could be a direct or indirect effect on the kidneys, which may precipitate disease and increase maternal mortality⁹⁵.

INFLUENZA

Symptoms of influenza include cough, fever, malaise, rhinitis, myalgias, headache, chills, and sore throat. Less common symptoms include nausea and vomiting, otitis, and conjunctiva burning. Signs of influenza include fever, tachycardia, facial flushing, clear nasal discharge, and cervical adenopathy.

Pregnant women are at high risk for severe complications of influenza during seasonal influenza periods⁹⁶ and pandemics^{97–100}. In addition, some studies suggest an increased risk for adverse outcomes among infants born to mothers infected with influenza during pregnancy^{101–104}.

Influenza viruses that infect humans are classified into 3 principal types (A, B, and C), of which types A and B are important causes of human disease. Types A and B are associated with seasonal epidemics; only type A viruses have caused pandemics. Influenza A viruses are further classified on the basis of 2 surface proteins, hemagglutinin (H) and neuraminidase (N). H1N1 designates a specific subtype of influenza A. Minor mutations that result in subtle changes in these proteins (antigenic drift) occur continuously. Because these mutations produce viruses that can be sufficiently different antigenically from previous influenza viruses, influenza vaccines must be updated annually. More dramatic changes in the surface proteins of influenza viruses, through mutation of nonhuman (e.g., avian or swine) viruses or reassortment of human and nonhuman viruses, result in the creation of novel human subtypes (termed antigenic shift). When novel subtypes that can be efficiently transmitted among humans target certain populations, a pandemic of influenza can occur¹⁰⁵.

Pregnancy has been the highest risk factor for increased illness and death for both pandemic and seasonal influenza². Although appropriate non-pregnant control groups were generally not available, mortality rates among pregnant women in the pandemics of 1918 and 1957 appeared to be abnormally high^{97, 99}. Among 1,350 reported cases of influenza among pregnant women during the pandemic of 1918, the proportion of deaths was reported to be 27%⁹⁷. Similarly, among a small case series of 86 pregnant women hospitalized in Chicago for influenza in 1918, 45% died⁹⁷. Among pregnancy-associated deaths in Minnesota during the 1957 pandemic, influenza was the leading cause of death, accounting for nearly 20% of deaths associated with pregnancy during the pandemic period; half of women of reproductive age who died were pregnant⁹⁹.

Pregnant women have also been shown to be at increased risk for influenza complications during seasonal influenza periods¹⁰². In a large study of >4,300 women of reproductive age during 19 influenza seasons, pregnant women were compared with postpartum women (a group considered to be most similar to pregnant women demographically and with regard to their health) and were found to be significantly more likely to be hospitalized for a cardiopulmonary event during the influenza season⁹⁶. The risk for hospitalization increased as pregnancy progressed, with women at term nearly 5 times more likely to be hospitalized than postpartum women⁹⁶. Similarly, during 3 influenza seasons in the late 1970s, rates of medical visits for acute respiratory disease were more than twice as high among pregnant women than non-pregnant women¹⁰⁶. At particularly high risk during the influenza season are pregnant women with underlying medical conditions for which influenza vaccination is recommended, such as asthma¹⁰⁷. On the basis of these data pregnant women are considered a population for which special considerations for prevention and treatment for influenza have been made.

Although certain infections are well recognized to increase the risk for adverse pregnancy outcomes, the effects of maternal influenza infection on the fetus are not well understood.

Viremia is believed to occur infrequently in influenza¹⁰⁸, and placental transmission of the virus also appears to be rare¹⁰⁹. However, even in the absence of fetal viral infection, murine models suggest that adverse effects can still occur. Prenatal influenza infection in the mouse has been associated with histopathologic changes in the brain¹¹⁰ and behavioral alterations¹¹¹ in offspring. Although influenza virus RNA has not been detected in the fetal brain, these changes suggest that fetal effects could be secondary to the maternal inflammatory response, rather than the result of a direct viral effect¹¹².

Adverse pregnancy outcomes have been reported following previous influenza pandemics. During the influenza pandemic of 1918, remarkably high rates of spontaneous abortion and preterm birth were reported^{97, 98}, especially among women with pneumonia (for example, in one study, >50% of pregnancies in which the pregnant woman had influenza and accompanying pneumonia were not carried successfully to term)⁹⁷. During the Asian influenza pandemic of 1957, studies suggested a possible increase in defects of the central nervous system^{102–104} and several other adverse outcomes, including birth defects, spontaneous pregnancy loss¹⁰⁴, fetal death, and preterm delivery¹⁰⁰. Studies of the effects of seasonal influenza infection on the fetus have been contradictory. A small increased risk for birth defects in general and for specific birth defects have been observed in some but not all studies¹⁰¹. Using data from a recent case-control study, investigators showed that mothers of infants with any type of birth defect were slightly more likely to report influenza during early pregnancy than mothers of control infants (adjusted odds ratio 1.4; 95% confidence intervals 1.3–1.6), with statistically significant associations for cleft lip with or without cleft palate, and neural tube and congenital heart defects. Verification of maternal report of influenza illness with prospectively collected clinical data was possible for similar numbers of case and control infants¹⁰¹, which suggests that recall bias was unlikely to explain the association. The risk associated with influenza was reduced for women who received treatment with antipyretic medications and for those who had taken folic acid before and during early pregnancy¹⁰¹.

Associations between maternal influenza infection after both pandemic and seasonal influenza and outcomes observed long after birth have been reported. Associations between maternal influenza infection and childhood leukemia¹¹³, schizophrenia¹¹⁴, and Parkinson disease¹¹⁵ have been suggested by some studies. Even if the influenza virus does not have a direct effect on the fetus, fever that often accompanies influenza infection could have adverse effects. Both animal and human epidemiologic studies suggest that hyperthermia is associated with an increased risk for adverse outcomes¹¹⁶, especially neural tube defects¹¹⁷. Factors that might attenuate this risk include shorter fever duration¹¹⁸, use of fever-reducing medications^{118–120}, and use of folic acid-containing supplements¹¹⁹. However, there is evidence that vaccination works and is protective for both mother and fetus, especially for high-risk subpopulations, such as immunosuppressed pregnant women. A recent study in South Africa showed that IIV3 vaccination in pregnant HIV-uninfected and HIV-infected women was immunogenic and provided protection against confirmed influenza¹²¹.

CDC Recommendations: The CDC currently recommends influenza vaccine for all pregnant women in any trimester during flu season. Furthermore, pregnant women with symptoms of

influenza should be screened and treated immediately, especially those with co-morbid medical conditions.

EBOLA and LASSA FEVER

Ebola and Lassa viruses cause hemorrhagic fevers that have been reported mainly in Africa¹²². However, as a result of the most recent Ebola epidemic with infected individuals traveling outside of Africa, these types of viral infections became a global challenge, especially due to the potential effect in pregnancy and the newborn.

Ebola virus disease is a rare but severe viral hemorrhagic fever that is caused by five different species of Ebola virus. The major outbreaks of Ebola Hemorrhagic fever (EHF) occurred in Africa, especially in resource-constrained regions. The virus species (Zaire ebolavirus) causing the current epidemic was identified in 1976 in Kikwit, the Democratic Republic of the Congo. During that epidemic, the numbers of infected women were higher than men, though largely due to cultural practices rather than biological differences^{5, 123, 124}.

During previous epidemics, mortality among pregnant women was found to be higher than in the general population or non-pregnant women. In the 1976 epidemic, 46% of the 177 Ebola-infected women were pregnant and the overall mortality among pregnant women was 89%. A major clinical manifestation was vaginal and uterine bleeding with 93% mortality within 10 days of illness onset^{125, 126}. Moreover, a significant increase in preterm birth and abortion has been reported in the different epidemics^{5, 127}. Twenty three percent of infected pregnant women had spontaneous abortions in the 1976 epidemic; while 67% of pregnancies were reported to end with abortion in the 1995 epidemic^{125, 126, 128}.

Lassa fever or Lassa hemorrhagic fever (LHF) is an acute viral hemorrhagic fever caused by the Lassa virus and was first described in 1969 in the town of Lassa in Nigeria^{122, 129, 130}. Lassa fever is endemic in eastern Sierra Leone where it is a major cause of mortality, especially in pregnant women¹³¹. Interestingly, the condition of the mother improved rapidly after evacuation of the uterus whether by spontaneous abortion or normal delivery⁴. Ten of 26 women without delivery died, while only four of 39 women that delivered died⁴.

Viral infection and pregnancy: old and new concepts

One of the main hypotheses used to explain the increased risk for infection and mortality during pregnancy has been the concept of “pregnancy as an immune suppressed condition”¹³². The “paradox of pregnancy” as a semi-allograft has been approached from the point of perspective of organ transplantation. The view of the fetus as an organ transplant, and the requirement of systemic immune suppression for the success of the transplant, led to the proposal of pregnancy as a condition of systemic immune suppression as a requirement for the success of the pregnancy. From this point of view, similarly as in immune suppressed patients, pregnancy is in a state of weak immunologic protection.

This concept has been tested for many years in animal models as well as in patients with fertility problems. Unfortunately, after almost 50 years of research following this assumption, there is a lack of evidence to support this hypothesis.

Therefore, it is important to evaluate the immunologic aspects associated with pregnancy in order to further understand the potential biological reasons associated with the risk of infection during pregnancy. One wonders why the model of transplantation may not represent the correct immunological situation of pregnancy: During transplantation there is a major influx of foreign antigens as a result of the introduction of a fully foreign organ. Under this circumstance the host immune system acutely reacts to the foreign antigens and mounts an immunologic response to reject the source of foreign antigens. During pregnancy the process is different. Pregnancy is a slow and gradual process where paternal/fetal antigens are released in a gradual and increasing manner as the blastocyst grows into an embryo and then into a fetus. The exposure of small amounts of foreign antigens during this process may actually induce *tolerance* rather than rejection. Consequently, pregnancy, contrary to transplantation, does not require systemic immune suppression.

A second aspect that has been ignored for many years is the role of the placenta. Pregnant women represent an immunologically unique population because their immune system is influenced by signals originating from the placenta^{7, 133}. The presence of the fetus and placenta alters maternal immunity and physiology to sustain and protect the pregnancy. We and others have shown that the placenta may function as an immune modulatory organ that regulates the immune responses of cells present both at the implantation site as well as systemically^{134–136}. However, this modulation is not suppressive, but protective. In general, the maternal immune system is well prepared to control infections and ensure the survival of the fetus. Paradoxically, the placenta is also a target for viral infections. Recent studies suggest that although the placenta can be infected by viruses it has a unique capacity to prevent expansion of the virus and transmission to the fetus^{8, 137, 138, 133}. What is not clear is the effect of a viral infection on the normal homeostasis of the placenta and its interaction with the maternal immune system. As discussed below in more detail, a viral infection of the placenta might affect the normal homeostasis at the implantation site, as well as the systemic immune system of the mother, which will determine the type of immune response that is elicited in the presence of normal or abnormal microorganisms.

Pregnancy complications are the result of polymicrobial infections

Preterm delivery, defined as delivery prior to 37 completed weeks of gestation, is one of the most frequent obstetrical complications, occurring in 12% of all deliveries in the United States^{139–141}. It is the leading cause of neonatal morbidity, and a major cause of neonatal mortality. Premature infants suffer chronic long-term health issues, and even severe neurological impairment if they survive. Maternal consequences range from caesarean delivery, labeling of “high-risk” in subsequent pregnancies with the need for intense surveillance with subsequent anxiety, and the stress of life-long care for a child. In addition, the health care costs of caring for these preterm infants after delivery likely exceeds \$26 billion dollars a year^{108, 142, 143}. While this complication of pregnancy has major medical, social, and economic consequences, the cause of spontaneous preterm birth is unknown.

It has been well established that adverse pregnancy outcomes have been linked to bacterial infections, such as chorioamnionitis and pyelonephritis^{39, 144–146, 147}. On the contrary, viral infections have long-been considered benign, with a few exceptions, some of which are

listed above. For example, in the clinical setting, a pregnant woman with a cold or viral upper respiratory infection is treated symptomatically, and usually there is no concern for the pregnancy¹⁴⁸. To be fair, the reasons for this stem from our lack of evidence of the adverse pregnancy outcomes that can occur as a result of these infections, and the lack of effective measures to prevent these outcomes. Nevertheless, the sequelae of a viral infection can still lead to opportunistic infections that then can adversely affect the pregnancy. We investigated this novel approach to the problem of preterm labor and delivery: a polymicrobial etiology. This model illustrates how a viral infection during pregnancy, leads to an accentuated response to a low dose of bacterial product, leading to preterm labor and delivery^{133, 136}.

Our knowledge of the normal flora in the female reproductive tract and placenta has expanded in recent years. New technologies and methodologies have allowed us to further characterize the microorganisms in these two locations^{149–151}. We see how commensal bacteria in the female reproductive tract can have relevant effects on the local immune function^{152, 153}. Furthermore, it has now become apparent that multiple different bacteria and viruses reside in the placenta and amniotic fluid, locations once thought to be sterile^{1154, 155}. However, bacterial infection has been associated with a major cause of preterm labor¹⁵⁶. But when do bacteria become a risk for the success of pregnancy? Our lab has recently examined the role of infection in the pathophysiology of preterm delivery. In contrast to multiple studies that have looked at single organisms as the lone etiology of premature labor and delivery, we investigated a different approach. Using a murine model of viral infection of the placenta we characterized the subsequent response to bacteria. The viral infection was simulated using a murine herpes virus, MHV-68^{136, 157}. This virus is homologous to 2 human herpes viruses: Epstein Barr virus, and human herpes virus 8 (Kaposi's sarcoma-associated virus)¹⁵⁸. C57BL/6 pregnant mice were separated into 4 groups. The first group (the control group) was injected with DMEM media (vehicle) on day E8.5, then PBS on day E15.5. The second group was injected with DMEM on day E8.5, then 20ug/kg of LPS on day E15.5. The third group was injected with 1×10^6 plaque-forming units of MHV-68 on day E8.5, then, PBS on day E15.5. The last group was injected with MHV on day E8.5, then LPS on day E15.5. The mice in the control and MHV-only group were unaffected and delivered normal-sized, term pups. The LPS only group had a preterm delivery rate of 29%, while the group injected with MHV then LPS all delivered preterm within 24 hours after LPS injection. Furthermore, significant inflammatory responses were noted in the placenta and decidua of the MHV with LPS group (group 4).

In addition to preterm delivery the group that was injected with both MHV and LPS also had adverse fetal outcomes. Parallel experiments were performed where the mice were divided into the four groups and injected as above, then were sacrificed prior to delivery to examine the gestational sacs. The gestational sacs of the control, LPS-alone, and MHV-alone groups showed no visible effect. However, the sacs with the MHV and LPS treatment together showed marked necrosis and anomalies in the gestational sacs. Furthermore, all these fetuses demonstrated anatomical abnormalities, such as hydrocephalus and pulmonary and pericardial hemorrhage¹³³.

Interestingly, no virus was detected in the fetuses of MHV-infected moms, as determined by using a limited dilution plaque assay and confirmed by PCR. In contrast, isolated mouse embryonic fibroblast cells were able to be infected in-vitro with MHV-68, which suggests that the placenta provides immunologic protection to the fetus from viral infection during pregnancy¹⁵⁹. However, even though no viral titers were detected in the fetuses, evidence of a fetal inflammatory response was noted as shown by elevated levels of IL-1, MCP-1, MIP1- β , IFN- γ and TNF- α . The inflammatory response of the fetus may explain a developmental pathway of the observed anatomic changes. Moreover, the response of the fetal-placental unit during pregnancy can have far-reaching consequences, leading to postnatal developmental adverse outcomes, such as schizophrenia and psychosis^{160–162}. Based on these findings, we propose that a viral infection of the placenta (the first hit) may affect the normal interaction with the local bacteria (the second hit), leading to a “pro-inflammatory cytokine storm” that leads to preterm birth¹³³. Consequently, infection leading to preterm birth is a polymicrobial condition.

This new emerging data sheds light on an area of pregnancy once thought to be pure and pristine: the maternal-fetal interface and the placenta. In addition, immune effects of interactions between microorganisms can lead to significant perinatal outcomes, such as preterm delivery. Armed with the new information of the microbial environment and possible adverse pregnancy outcomes that can be associated with viruses and bacteria, new strategies are necessary to detect these microorganisms, even in asymptomatic pregnant women. By understanding this polymicrobial mechanism of disease, we can develop management and prevention strategies to decrease the incidence of preterm birth. Identifying the “first hit” in the cascade can allow opportunities for intervention and possible prevention of premature labor and delivery. Only then will this devastating obstetrical problem be controlled and neonatal outcomes improved.

Acknowledgment

This study is in part funded by grants from the National Institute of Health, NICDH P01HD054713 and 3N01 HD23342 and the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services.

MS is a WRHR scholar and her work is part funded from the K12HD047018-09 training grant of the Eunice Kennedy Shriver NICHD, NIH and the Albert McKern Scholar Award.

Bibliography

1. Gervasi MT, Romero R, Bracalente G, Chaiworapongsa T, Erez O, Dong Z, Hassan SS, Yeo L, Yoon BH, Mor G, Barzon L, Franchin E, Militello V, Palu G. Viral invasion of the amniotic cavity (VIAC) in the midtrimester of pregnancy. *J Matern Fetal Neona*. 2012
2. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. *N Engl J Med*. 2014; 370:2211–2218. [PubMed: 24897084]
3. Kwon JY, Romero R, Mor G. New insights into the relationship between viral infection and pregnancy complications. *Am J Reprod Immunol*. 2014; 71:387–390. [PubMed: 24702790]
4. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. *BMJ*. 1988; 297:584–587. [PubMed: 3139220]

5. Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA. What Obstetrician-Gynecologists Should Know About Ebola: A Perspective From the Centers for Disease Control and Prevention. *Obstet Gynecol.* 2014
6. Romero R, Miranda J, Chaiworapongsa T, Korzeniewski SJ, Chaemsaihong P, Gotsch F, Dong Z, Ahmed AI, Yoon BH, Hassan SS, Kim CJ, Yeo L. Prevalence and Clinical Significance of Sterile Intra-amniotic Inflammation in Patients with Preterm Labor and Intact Membranes. *Am J Reprod Immunol.* 2014
7. Kwon JY, Romero R, Mor G. New Insights into the Relationship between Viral Infection and Pregnancy Complications. *Am J Reprod Immunol.* 2014
8. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. *Semin Reprod Med.* 2007; 25:21–39. [PubMed: 17205421]
9. Chernyshov V, Slukvin I, Bondarenko G. Phenotypic characterization of CD7+, CD3+, and CD8+ lymphocytes from first trimester human decidua using two color flow cytometry. *Am J Reprod Immunol.* 1993; 29:5–16. [PubMed: 7684920]
10. Gottlieb SLDJ, Schmid DS, Bolan G, Iatesta M, Malotte CK, et al. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. *J Infect Dis.* 2002; 186:1381–1389. [PubMed: 12404152]
11. Xu F, Lee FK, Morrow RA, Sternberg MR, Luther KE, Dubin G, Markowitz LE. Seroprevalence of herpes simplex virus type 1 in children in the United States. *J Pediatr.* 2007; 151:374–377. [PubMed: 17889072]
12. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, Watts DH, Berry S, Herd M, Corey L. The acquisition of herpes simplex virus during pregnancy. *N Engl J Med.* 1997; 337:509–515. [PubMed: 9262493]
13. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. *Jama.* 2006; 296:964–973. [PubMed: 16926356]
14. Enright AMPC. Neonatal herpes infection: Diagnosis, treatment and prevention. *Semin Neonatol.* 2002:283–291. [PubMed: 12401298]
15. Brown ZAWA, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. *JAMA.* 2003:203–209. [PubMed: 12517231]
16. Brown ZABJ, Selke S, Ashley R, Watts DH, Corey L. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: Relationship to preterm labor. *Obstet Gynecol.* 1996:483–488. [PubMed: 8602295]
17. Brown ZA, Benedetti J, Selke S, Ashley R, Watts DH, Corey L. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. *Obstet Gynecol.* 1996; 87:483–488. [PubMed: 8602295]
18. Brown ZAGC, Wald A, Morrow RA, Corey L. Genital herpes complicating pregnancy. *Obstet Gynecol.* 2005:845–856. [PubMed: 16199646]
19. Sheffield LH JS, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: A systematic review. *Obstet Gynecol.* 2003:1396–1403.
20. Andrews WWKD, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. *Am J Obstet Gynecol.* 2006:774–781. [PubMed: 16522412]
21. Watts ZB DH, Money D, Selke S, Huang ML, Sacks SL, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol.* 2003:836–843.
22. Haun L, Kwan N, Hollier LM. Viral infections in pregnancy. *Minerva Ginecol.* 2007; 59:159–174. [PubMed: 17505458]
23. Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. *Am J Obstet Gynecol.* 2007; 196:43 e41–46 e41. [PubMed: 17240228]
24. Kimberlin DWLC-Y, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. *Pediatrics.* 2001:223–229. [PubMed: 11483781]

25. Kohelet DKN, Sadan O, Somekh E. Herpes simplex virus infection after vacuum-assisted vaginally delivered infants of symptomatic mothers. *J Perinatol.* 2004;147–149. [PubMed: 14973511]
26. O'Boyle, MKPD. Fetal infections. In: NDe al. , editor. *Diagnostic Imaging of Fetal Anomalies.* Philadelphia: Lippincott Williams & Wilkins; 2003. p. 745-776.
27. Gibbs, RSSR. Maternal and fetal infectious disorders. In: RR Creasy, RK., editor. *Maternal-Fetal Medicine.* Philadelphia: WB Saunders; 1999. p. 659-724.
28. ACOG Practice Bulletin. Perinatal Viral and Parasitic Infections. 2000
29. Enders GME, Cradock-Watson J, Bolley I, Ridehalgh. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. *M Lancet.* 1994; 343:1548–1551. [PubMed: 7802767]
30. SJ C. Varicella in pregnancy. *Semin Perinatol.* 1998; 22:339–346. [PubMed: 9738999]
31. Pastuszak ALLM, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. *N Engl J Med.* 1994; 330
32. Higa K, Dan K, Manabe H. Varicella-zoster virus infections during pregnancy: hypothesis concerning the mechanisms of congenital malformations. *Obstet Gynecol.* 1987; 69:214–222. [PubMed: 3027637]
33. Lamont RF, Sobel JD, Carrington D, Mazaki-Tovi S, Kusanovic JP, Vaisbuch E, Romero R. Varicella-zoster virus (chickenpox) infection in pregnancy. *Bjog.* 2011; 118:1155–1162. [PubMed: 21585641]
34. Lamont RF. The role of infection in preterm labour and birth. *Hosp Med.* 2003; 64:644–647. [PubMed: 14671873]
35. Lamont RF. Infection in the prediction and antibiotics in the prevention of spontaneous preterm labour and preterm birth. *Bjog.* 2003; 110(Suppl 20):71–75. [PubMed: 12763116]
36. Lamont RF, Nhan-Chang CL, Sobel JD, Workowski K, Conde-Agudelo A, Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. *Am J Obstet Gynecol.* 2011; 205:177–190. [PubMed: 22071048]
37. Lamont RF, Sobel J, Mazaki-Tovi S, Kusanovic JP, Vaisbuch E, Kim SK, Uldbjerg N, Romero R. Listeriosis in human pregnancy: a systematic review. *Journal of perinatal medicine.* 2011; 39:227–236. [PubMed: 21517700]
38. Syggelou A, Iacovidou N, Kloudas S, Christoni Z, Papaevangelou V. Congenital cytomegalovirus infection. *Annals of the New York Academy of Sciences.* 2010; 1205:144–147. [PubMed: 20840266]
39. Ornoy A, Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. *Reprod Toxicol.* 2006; 21:399–409. [PubMed: 16580941]
40. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. *Reviews in medical virology.* 2007; 17:253–276. [PubMed: 17579921]
41. McCarthy M, Auger D, Whittemore SR. Human cytomegalovirus causes productive infection and neuronal injury in differentiating fetal human central nervous system neuroepithelial precursor cells. *Journal of human virology.* 2000; 3:215–228. [PubMed: 10990168]
42. Picone O, Vauloup-Fellous C, Cordier AG, Guitton S, Senat MV, Fuchs F, Ayoubi JM, Grangeot Keros L, Benachi A. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. *Prenat Diagn.* 2013; 33:751–758. [PubMed: 23553686]
43. Tassin M, Martinovic J, Mirand A, Peigue-Lafeuille H, Picone O, Benachi A, Vauloup-Fellous C. A case of congenital Echovirus 11 infection acquired early in pregnancy. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.* 2014; 59:71–73. [PubMed: 24332364]
44. Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. *Pediatrics.* 1999; 104:55–60. [PubMed: 10390260]

45. Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. *The Journal of pediatrics*. 1997; 130:624–630. [PubMed: 9108862]
46. Yinon Y, Farine D, Yudin MH. Screening, diagnosis, and management of cytomegalovirus infection in pregnancy. *Obstetrical & gynecological survey*. 2010; 65:736–743. [PubMed: 21375790]
47. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, Cherney DZ, Hladunewich MA. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. *Circulation*. 2010; 122:1846–1853. [PubMed: 20956209]
48. Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. *Clin Infect Dis*. 1995; 20:665–670. [PubMed: 7756493]
49. Dontigny LAM, Martel MJ, Biringer A, Cormier J, Delaney M, Gleason T, Leduc D, Martel MJ, Penava D, Polsky J, Roggensack A, Rowntree C, Wilson AK. Society of Obstetricians and Gynecologists of Canada.: Rubella in pregnancy. *J Obstet Gynaecol Can*. 2008; 30:152–168. [PubMed: 18254998]
50. Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity. *Clinical microbiology reviews*. 2000; 13:571–587. [PubMed: 11023958]
51. Gabbe SG, Niebyl JRSJ. Obstetrics normal and problem pregnancies. 2002:1328–1330.
52. Centers for Disease Control and Prevention (CDC). Epidemiology of HIV/AIDS--United States, 1981–2005. *MMWR Morb Mortal Wkly Rep*. 2006; 55:589–592. [PubMed: 16741494]
53. Ciaranello AL, Perez F, Keatinge J, Park JE, Engelsmann B, Maruva M, Walensky RP, Dabis F, Chu J, Rusibamayila A, Mushavi A, Freedberg KA. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. *PLoS medicine*. 2012; 9:e1001156. [PubMed: 22253579]
54. Wang B, Losina E, Stark R, Munro A, Walensky RP, Wilke M, Martin D, Lu Z, Freedberg KA, Wood R. Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 count. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*. 2011; 101:253–257. [PubMed: 21786730]
55. Venkatesh KK, Cu-Uvin S. Anatomic and hormonal changes in the female reproductive tract immune environment during the life cycle: implications for HIV/STI prevention research. *Am J Reprod Immunol*. 2014; 71:495–504. [PubMed: 24832617]
56. Haase AT. Overview of the landscape of HIV prevention. *Am J Reprod Immunol*. 2014; 71:490–494. [PubMed: 24702688]
57. Fahey JV, Bodwell JE, Hickey DK, Ghosh M, Muia MN, Wira CR. New approaches to making the microenvironment of the female reproductive tract hostile to HIV. *Am J Reprod Immunol*. 2011; 65:334–343. [PubMed: 21223421]
58. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV. Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. *Am J Reprod Immunol*. 2011; 65:196–211. [PubMed: 21294805]
59. Wira CR, Veronese F. Mucosal immunity in the male and female reproductive tract and prevention of HIV transmission. *Am J Reprod Immunol*. 2011; 65:182–185. [PubMed: 21294802]
60. Hollinger, FBTJ. KDaHP. Hepatitis A virus. In: Fields, BN., editor. *Fields Virology*. 3rd edn.. 1996. p. 735-782.
61. Lemon SM. Type A viral hepatitis: epidemiology, diagnosis, and prevention. *Clin Chem*. 1997; 43:1494–1505. [PubMed: 9265900]
62. JT Stapleton, SL. Hepatitis A and hepatitis E. In: JM Hoeprich, PD.; Ronald, AR., editors. *Infectious Diseases*. Philadelphia: Lippincott Co; 1994. p. 790-797.
63. Hunt J. HLA and maternal-fetal recognition. *FASEB J*. 1992; 6:2344–2348. [PubMed: 1544544]
64. Leikin ELA, Garry D, Tejani N. Intrauterine transmission of hepatitis A virus. *Obstet Gynecol*. 1996; 88:690–691. [PubMed: 8841254]

65. Erkan TKT, Cullu F, Tümay GT. A case of vertical transmission of hepatitis A virus infection. *Acta Paediatr.* 1998; 87:1008–1017. [PubMed: 9764900]
66. Renge VD RL, Chitambar SD, Arankalle VA. Vertical transmission of hepatitis A. *Indian J Pediatr.* 2002; 69:535–541. [PubMed: 12139145]
67. Duff P. Hepatitis in pregnancy. *Semin Perinatol.* 1998; 22:277–283. [PubMed: 9738992]
68. Duff P. Perinatal infectious disease. *Semin Perinatol.* 1998; 22:241. [PubMed: 9738987]
69. D Ganem, RS. Hepadnaviridae: The Viruses and Their Replication. In: DKe al. , editor. *Fields Virology*. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2923-2969.
70. Thompson E. Apoptosis and Steroid Hormones. *Mol Endocrinol.* 1994; 8:665. [PubMed: 7935482]
71. A Maheshwari SR. PJ Thuluvath Acute hepatitis C. *Lancet.* 2008; 372:321–332. [PubMed: 18657711]
72. EE Mast MA. HS Margolis Strategies to prevent and control hepatitis B and C virus infections: a global perspective. *Vaccine.* 1999; 17:1730–1733. [PubMed: 10194830]
73. Alter DK-M MJ, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med.* 1999; 341:556–562. [PubMed: 10451460]
74. Edlin TK BR, Raymond DB, Carden MR, Gourevitch MN. JD Rich Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. *Clin Infect Dis.* 2005; 40:S276–S285. [PubMed: 15768335]
75. Armstrong AW GL, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med.* 2006; 144:705–714. [PubMed: 16702586]
76. Williams I. Epidemiology of hepatitis C in the United States. *Am J Med.* 1999; 107:2S–9S. [PubMed: 10653448]
77. Armstrong MA GL, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. *Hepatology.* 2000; 31:777–782. [PubMed: 10706572]
78. CfDCa Prevention. , editor. CDC. Recommendation for prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic disease. Atlanta: 1998.
79. Bell EM BP, Terrault N, Hutin YJ. Prevention of hepatitis C in women. *Emerg Infect Dis.* 2004; 10:2035–2041. [PubMed: 16010740]
80. Garfein DV RS, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. *Am J Public Health.* 1996; 86:655–661. [PubMed: 8629715]
81. Alter M. Epidemiology of hepatitis C. *Eur J Gastroenterol Hepatol.* 1996; 8:19–23.
82. Jain NG S, Saade G, Hankins GD, Anderson GD. Hepatitis C in pregnancy. *Am J Perinatol.* 2007; 24:251–257. [PubMed: 17447189]
83. Ward GT-W C, Cotzias T, Hargreaves S, Regan L, Foster GR. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. *Gut.* 2000; 47:277–280. [PubMed: 10896922]
84. Staples DR CT Jr, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. *Clin Infect Dis.* 1999; 29:150–154. [PubMed: 10433578]
85. WHO. Hepatitis C Virus.
86. Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. *Seminars in pediatric infectious diseases.* 2005; 16:296–305. [PubMed: 16210109]
87. Bortolotti F, Iorio R, Resti M, Camma C, Marcellini M, Giacchino R, Marazzi MG, Verucchi G, Zancan L, Barbera C, Maggiore G, Vajro P, Giannattasio A, Bartolacci S. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. *J Hepatol.* 2007; 46:783–790. [PubMed: 17321633]
88. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *J Hepatol.* 2008; 48:335–352. [PubMed: 18096267]
89. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. *Hepatology.* 2001; 34:223–229. [PubMed: 11481604]

90. Yeung LT, Roberts EA. Hepatitis B in childhood: An update for the paediatrician. *Paediatrics & child health*. 2001; 6:655–659. [PubMed: 20084138]
91. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, Alter MJ. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis*. 2005; 192:1880–1889. [PubMed: 16267758]
92. Harrison T. Hepatitis E virus -- an update. *Liver*. 1999; 19:171–177. [PubMed: 10395034]
93. Naik RA SR, Salunke PN, Mehrotra NN. A large waterborne viral hepatitis E epidemic in Kanpur, India. *Bull World Health Organ*. 1992; 70:597–604. [PubMed: 1464145]
94. Organization WH. Introduction of hepatitis B vaccine into childhood immunization services. Geneva: 2001.
95. Patra SKA, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. *Ann Intern Med*. 2007; 147:28–33. [PubMed: 17606958]
96. Neuzil KMRG, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. *Am J Epidemiol*. 1998; 148:1094–1102. [PubMed: 9850132]
97. JW H. Influenza occurring in pregnant women. *JAMA*. 1919; 72:978–980.
98. Nuzum JWPI, Stangl FH, Bonar BE. Pandemic influenza and pneumonia in a large civilian hospital. *JAMA*. 1918; 71:1562–1567.
99. Freeman DWBA. Deaths from Asian influenza associated with pregnancy. *Am J Obstet Gynecol*. 1959; 78:1172–1177. [PubMed: 13824729]
100. Hardy JMAE, Mannini A, Medearis DN Jr, Cooke RE. The effect of Asian influenza on the outcome of pregnancy, Baltimore, 1957–1958. *Am J Public Health*. 1961; 51:1182–1190.
101. Acs NBF, Puho E, Czeizel AE. Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. *Birth Defects Res A Clin Mol Teratol*. 2005; 73:989–996. [PubMed: 16323157]
102. Coffey VPJW. Maternal influenza and congenital deformities. A follow-up study. *Lancet*. 1963; 1:748–751. [PubMed: 14021958]
103. Saxen LHL, Sjostedt JE, Hakosalo J, Hakosalo H. Asian influenza during pregnancy and congenital malformations. *Acta Pathol Microbiol Scand*. 1960; 49:114–126. [PubMed: 14442130]
104. Wilson MGSA. Teratogenic effects of Asian influenza. An extended study. *JAMA*. 1969; 210:336–344. [PubMed: 5394374]
105. Services UDoHaH. HHS pandemic influenza plan.
106. Mullooly JPBW, Nolan TF Jr. Risk of acute respiratory disease among pregnant women during influenza A epidemics. *Public Health Rep*. 1986; 101:205–216. [PubMed: 3083477]
107. Cox SPS, McPheeters M, Jamieson DJ, Kourtis AP, Meikle S. Hospitalizations with respiratory illness among pregnant women during influenza season. *Obstet Gynecol*. 2006; 107:1315–1322. [PubMed: 16738158]
108. Zou S. Potential impact of pandemic influenza on blood safety and availability. *Transfus Med Rev*. 2006; 20:181–190. [PubMed: 16787826]
109. Irving WLJD, Stephenson T, Laing P, Jameson C, Oxford JS, et al. Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. *BJOG*. 2000; 107:1282–1291. [PubMed: 11028582]
110. Fatemi SHEJ, Kanodia R, Kist D, Emamian ES, Patterson PH, et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. *Cell Mol Neurobiol*. 2002; 22:25–33. [PubMed: 12064515]
111. Shi LFS, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. *J Neurosci*. 2003; 23:297–302. [PubMed: 12514227]
112. Shi LTN, Patterson PH. Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. *Int J Dev Neurosci*. 2005; 23:299–305. [PubMed: 15749254]

113. Kwan MLMC, Crouse V, Buffler PA. Maternal illness and drug/medication use during the period surrounding pregnancy and risk of childhood leukemia among offspring. *Am J Epidemiol.* 2007; 165:27–35. [PubMed: 17035343]
114. Ebert TKM. Prenatal exposure to influenza and the risk of subsequent development of schizophrenia. *Isr Med Assoc J.* 2005; 7:35–43. [PubMed: 15658144]
115. Takahashi MYT. A possible role of influenza A virus infection for Parkinson's disease. *Adv Neurol.* 2001; 86:91–104. [PubMed: 11554013]
116. MJ E. Review: hyperthermia and fever during pregnancy. *Birth Defects. Res A Clin Mol Teratol.* 2006; 76:507–523.
117. Moretti MEB-OB, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. *Epidemiology.* 2005; 16:216–225. [PubMed: 15703536]
118. Suarez LFM, Hendricks K. The effect of fever, febrile illnesses, and heat exposures on the risk of neural tube defects in a Texas-Mexico border population. *Birth Defects Res A Clin Mol Teratol.* 2004; 70:815–824. [PubMed: 15468073]
119. Shaw GMNV, Carmichael SL, Lammer EJ, Finnell RH, Rosenquist TH. Maternal periconceptional vitamins: interactions with selected factors and congenital anomalies? *Epidemiology.* 2002; 13:625–630. [PubMed: 12410002]
120. Botto LDEJ, Mulinare J, Lynberg MC, Liu Y. Maternal fever, multivitamin use, and selected birth defects: evidence of interaction? *Epidemiology.* 2002; 13:485–493. [PubMed: 12094106]
121. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, Ortiz JR, Venter M, Violari A, Neuzil KM, Simoes EA, Klugman KP, Nunes MC, Maternal Flu Trial T. Influenza vaccination of pregnant women and protection of their infants. *N Engl J Med.* 2014; 371:918–931. [PubMed: 25184864]
122. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. *J Infect Dis.* 1987; 155:437–444. [PubMed: 3805771]
123. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, Muyembe-Tamfum JJ, Bwaka MA, De Roo A, Colebunders R. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. *J Infect Dis.* 1999; 179(Suppl 1):S13–S14. [PubMed: 9988158]
124. Guimard Y, Bwaka MA, Colebunders R, Calain P, Massamba M, De Roo A, Mupapa KD, Kibadi K, Kuvula KJ, Ndaberey DE, Katwili KR, Mapanda BB, Nkuku OB, Fleerackers Y, Van den Enden E, Kipasa MA. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. *J Infect Dis.* 1999; 179(Suppl 1):S268–S273. [PubMed: 9988194]
125. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, Katwili KR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, Van den Enden E, Van den Enden E. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. *J Infect Dis.* 1999; 179(Suppl 1):S1–S7. [PubMed: 9988155]
126. Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A, Kuvula K, Kibadi K, Massamba M, Ndaberey D, Colebunders R, Muyembe-Tamfum JJ. Ebola hemorrhagic fever and pregnancy. *J Infect Dis.* 1999; 179(Suppl 1):S11–S12. [PubMed: 9988157]
127. Okware SI, Omaswa FG, Zaramba S, Opio A, Lutwama JJ, Kamugisha J, Rwaguma EB, Kagwa P, Lamunu M. An outbreak of Ebola in Uganda. *Tropical medicine & international health : TM & IH.* 2002; 7:1068–1075. [PubMed: 12460399]
128. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. *J Infect Dis.* 1999; 179(Suppl 1):S18–S23. [PubMed: 9988160]
129. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. Clinical virology of Lassa fever in hospitalized patients. *J Infect Dis.* 1987; 155:456–464. [PubMed: 3805773]

130. McCormick JB, King IJ, Webb PA, Johnson KM, O'Sullivan R, Smith ES, Trippel S, Tong TC. A case-control study of the clinical diagnosis and course of Lassa fever. *J Infect Dis.* 1987; 155:445–455. [PubMed: 3805772]
131. Brabin BJ. Epidemiology of infection in pregnancy. *Reviews of infectious diseases.* 1985; 7:579–603. [PubMed: 3903938]
132. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts. transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. *British Journal of Experimental Pathology.* 1948; 29:58–69. [PubMed: 18865105]
133. Cardenas I, Mor G, Aldo P, Lang SM, Stabach P, Sharp A, Romero R, Mazaki-Tovi S, Gervasi M, Means RE. Placental viral infection sensitizes to endotoxin-induced pre-term labor: a double hit hypothesis. *Am J Reprod Immunol.* 2011; 65:110–117. [PubMed: 20712808]
134. Abrahams VM, Straszewski-Chavez SL, Guller S, Mor G. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. *Mol Human Reprod.* 2004; 10:55–63.
135. Mor G, Cardenas I. The immune system in pregnancy: A unique complexity. *Am J Reprod Immunol.* 2010; 63:425–433. [PubMed: 20367629]
136. Cardenas I, Means RE, Aldo P, Koga K, Lang SM, Booth C, Manzur A, Oyarzun E, Romero R, Mor G. Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. *J Immunol.* 2010; 185:1248–1257. [PubMed: 20554966]
137. Bayer A, Delorme-Axford E, Sleighter C, Frey TK, Trobaugh DW, Klimstra WB, Emert-Sedlak LA, Smithgall TE, Kinchington PR, Vadia S, Seveau S, Boyle JP, Coyne CB, Sadovsky Y. Human trophoblasts confer resistance to viruses implicated in perinatal infection. *Am J Obstet Gynecol.* 2014
138. Ouyang Y, Mouillet JF, Coyne CB, Sadovsky Y. Review: placenta-specific microRNAs in exosomes - good things come in nano-packages. *Placenta.* 2014; 35(Suppl):S69–S73. [PubMed: 24280233]
139. Chaiworapongsa T, Romero R, Kusanovic JP, Savasan ZA, Kim SK, Mazaki-Tovi S, Vaisbuch E, Ogge G, Madan I, Dong Z, Yeo L, Mittal P, Hassan SS. Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. *J Matern Fetal Neonatal Med.* 2010
140. Digiulio DB, Romero R, Kusanovic JP, Gomez R, Kim CJ, Seok KS, Gotsch F, Mazaki-Tovi S, Vaisbuch E, Sanders K, Bik EM, Chaiworapongsa T, Oyarzun E, Relman DA. Prevalence and Diversity of Microbes in the Amniotic Fluid, the Fetal Inflammatory Response, and Pregnancy Outcome in Women with Preterm Pre-Labor Rupture of Membranes. *Am J Reprod Immunol.* 2010; 64:38–57. [PubMed: 20331587]
141. Gibbs RS, Romero R, Hillier SL, Eschenbach DA, Sweet RL. A review of premature birth and subclinical infection. *Am J Obstet Gynecol.* 1992; 166:1515–1528. [PubMed: 1595807]
142. Goldenberg RL, Andrews WW, Goepfert AR, Faye-Petersen O, Cliver SP, Carlo WA, Hauth JC. The Alabama Preterm Birth Study: umbilical cord blood *Ureaplasma urealyticum* and *Mycoplasma hominis* cultures in very preterm newborn infants. *Am J Obstet Gynecol.* 2008; 198:43 e41–45 e41. [PubMed: 18166302]
143. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *Lancet.* 2008; 371:75–84. [PubMed: 18177778]
144. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. *Reprod Toxicol.* 2006; 21:446–457. [PubMed: 16480851]
145. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. *Reprod Toxicol.* 2006; 22:578–579. [PubMed: 16996245]
146. Ornoy A, Yaffe P, Zangen SW, Patlas N, Schwartz Z. Decreased response of osteoblasts obtained from aged Cohen diabetic sensitive rats to sex steroid hormones and 1,25OH2D3 in culture. *Odontology.* 2006; 94:38–43. [PubMed: 16998616]
147. Batts JA Jr. Chorioamnionitis. *The Journal of reproductive medicine.* 1976; 17:296–298. [PubMed: 994125]
148. Trinh QD, Izumi Y, Komine-Aizawa S, Shibata T, Shimotai Y, Kuroda K, Mizuguchi M, Ushijima H, Mor G, Hayakawa S. H3N2 influenza A virus replicates in immortalized human first

- trimester trophoblast cell lines and induces their rapid apoptosis. *Am J Reprod Immunol.* 2009; 62:139–146. [PubMed: 19694639]
149. White BA, Creedon DJ, Nelson KE, Wilson BA. The vaginal microbiome in health and disease. *Trends in endocrinology and metabolism: TEM.* 2011; 22:389–393. [PubMed: 21757370]
 150. Romero R, Hassan SS, Gajer P, Tarca AL, Fadrosch DW, Bieda J, Chaemsaitong P, Miranda J, Chaiworapongsa T, Ravel J. The vaginal microbiota of pregnant women who subsequently have spontaneous preterm labor and delivery and those with a normal delivery at term. *Microbiome.* 2014; 2:18. [PubMed: 24987521]
 151. Romero R, Hassan SS, Gajer P, Tarca AL, Fadrosch DW, Nikita L, Galuppi M, Lamont RF, Chaemsaitong P, Miranda J, Chaiworapongsa T, Ravel J. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. *Microbiome.* 2014; 2:4. [PubMed: 24484853]
 152. Mirmonsef P, Gilbert D, Veazey RS, Wang J, Kendrick SR, Spear GT. A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: implications for HIV and SIV susceptibility. *AIDS research and human retroviruses.* 2012; 28:76–81. [PubMed: 21595610]
 153. Mirmonsef P, Gilbert D, Zariffard MR, Hamaker BR, Kaur A, Landay AL, Spear GT. The effects of commensal bacteria on innate immune responses in the female genital tract. *American journal of reproductive immunology (New York, NY : 1989).* 2011; 65:190–195.
 154. Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN, Crucitti T, Vanham G, Arien KK. Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. *PLoS One.* 2012; 7:e43951. [PubMed: 22952818]
 155. Parent KN, Takagi Y, Cardone G, Olson NH, Ericsson M, Yang M, Lee Y, Asara JM, Fichorova RN, Baker TS, Nibert ML. Structure of a protozoan virus from the human genitourinary parasite *Trichomonas vaginalis*. *mBio.* 2013; 4
 156. McElrath TF, Allred EN, Van Marter L, Fichorova RN, Leviton A. Investigators ES. Perinatal systemic inflammatory responses of growth-restricted preterm newborns. *Acta Paediatr.* 2013; 102:e439–442. [PubMed: 23819682]
 157. Cardenas I, Aldo P, Koga K, Means R, Lang SH, Mor G. Subclinical viral infection in pregnancy lead to inflammatory process at the placenta with non-lethal fetal damage. *Am J Reprod Immunol.* 2010; 61 397-S312.
 158. Olivadoti M, Toth LA, Weinberg J, Opp MR. Murine gammaherpesvirus 68: a model for the study of Epstein-Barr virus infections and related diseases. *Comp Med.* 2007; 57:44–50. [PubMed: 17348290]
 159. Racicot K, Kwon JY, Aldo P, Silasi M, Mor G. Understanding the Complexity of the Immune System during Pregnancy. *Am J Reprod Immunol.* 2014; 72:107–116. [PubMed: 24995526]
 160. Shi L, Tu N, Patterson PH. Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. *Int J Dev Neurosci.* 2005; 23:299–305. [PubMed: 15749254]
 161. Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. *Schizophrenia bulletin.* 2009; 35:959–972. [PubMed: 18408229]
 162. Winter C, Djodari-Irani A, Sohr R, Morgenstern R, Feldon J, Juckel G, Meyer U. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP).* 2009; 12:513–524. [PubMed: 18752727]